DOSING AND TESTING REQUIREMENTS

SELECTED SAFETY INFORMATION

Immune-Mediated Pneumonitis

- KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases. Pneumonitis occurred in 3.4% (94/2799) of patients with various cancers receiving KEYTRUDA, including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%). Pneumonitis occurred in 8.2% (65/790) of NSCLC patients receiving KEYTRUDA as a single agent, including Grades 3-4 in 3.2% of patients, and occurred more frequently in patients with a history of prior thoracic radiation (17%) compared to those without (7.7%). Pneumonitis occurred in 6% (18/300) of HNSCC patients receiving KEYTRUDA as a single agent, including Grades 3-5 in 1.6% of patients, and occurred in 5.4% (15/276) of patients receiving KEYTRUDA in combination with platinum and fluorouracil (FU) as first-line therapy for advanced disease, including Grades 3-5 in 1.5% of patients.

- Monitor patients for signs and symptoms of pneumonitis. Evaluate suspected pneumonitis with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or recurrent Grade 2 pneumonitis.

NSCLC=non–small cell lung cancer; HNSCC=head and neck squamous cell carcinoma.

Before prescribing KEYTRUDA, please read the accompanying Prescribing Information. The Medication Guide also is available.
INDICATIONS

• KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.

• KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

• KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.

• KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.

• KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.

• KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.

• KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least 1 other prior line of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

• KEYTRUDA, in combination with platinum and FU, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).

• KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [combined positive score (CPS) ≥1] as determined by an FDA-approved test.

• KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

• KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

• KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

SELECTED SAFETY INFORMATION (continued)

Immune-Mediated Colitis

• KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 1.7% (48/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3 (1.1%), and 4 (<0.1%). Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for Grade 4 colitis.

Immune-Mediated Hepatitis (KEYTRUDA) and Hepatotoxicity (KEYTRUDA in Combination With Axitinib)

Immune-Mediated Hepatitis

• KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 0.7% (19/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3 (1.1%), and 4 (<0.1%). Monitor patients for changes in liver function. Administer corticosteroids for Grade 2 or greater hepatitis. Withhold KEYTRUDA for Grade 2 or greater hepatitis and, based on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.
INDICATIONS (continued)

- KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 (CPS ≥10), as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

- KEYTRUDA is indicated for the treatment of patients with locally advanced or mUC who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

- KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)
  - solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, or
  - colorectal cancer that has progressed following treatment with fluoropyrimidine, oxaliplatin, and irinotecan.

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.

- KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

- KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

- KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

- KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

SELECTED SAFETY INFORMATION (continued)

Immune-Mediated Hepatitis (KEYTRUDA) and Hepatotoxicity (KEYTRUDA in Combination With Axitinib) (continued)

Hepatotoxicity in Combination With Axitinib

- KEYTRUDA in combination with axitinib can cause hepatic toxicity with higher than expected frequencies of Grades 3 and 4 alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations compared to KEYTRUDA alone. With the combination of KEYTRUDA and axitinib, Grades 3 and 4 increased ALT (20%) and increased AST (13%) were seen. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering corticosteroids as needed.

HER2/neu=human epidermal growth factor receptor 2.

Before prescribing KEYTRUDA, please read the accompanying Prescribing Information. The Medication Guide also is available.
### DOSING AND TESTING REQUIREMENTS FOR KEYTRUDA

<table>
<thead>
<tr>
<th>Indication</th>
<th>Testing Required</th>
<th>Dose</th>
<th>Administered Intravenously</th>
<th>Duration of Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-line Metastatic Nonsquamous NSCLC in Combination With Pemetrexed and Platinum Chemotherapy</td>
<td>No testing for PD-L1 EGFR and ALK negative</td>
<td>Fixed 200 mg</td>
<td>Over 30 minutes every 3 weeks&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Treatment should continue until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.</td>
</tr>
<tr>
<td>First-line Metastatic Squamous NSCLC in Combination With Carboplatin and Either Paclitaxel or Paclitaxel Protein-bound</td>
<td>No</td>
<td>Fixed 200 mg</td>
<td>Over 30 minutes every 3 weeks&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Treatment should continue until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.</td>
</tr>
<tr>
<td>First-line Advanced or Metastatic NSCLC</td>
<td>PD-L1 expression (TPS ≥1%)&lt;sup&gt;a&lt;/sup&gt; EGFR and ALK negative</td>
<td>Fixed 200 mg, in combination with 5 mg axitinib</td>
<td>Over 30 minutes every 3 weeks&lt;sup&gt;b&lt;/sup&gt;; axitinib is administered orally twice daily</td>
<td></td>
</tr>
<tr>
<td>Second-line or Greater Metastatic NSCLC</td>
<td>PD-L1 expression (TPS ≥1%)&lt;sup&gt;a&lt;/sup&gt; If EGFR or ALK positive, should have disease progression on FDA-approved therapy for these aberrations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Third-line or Greater Metastatic SCLC</td>
<td>No</td>
<td>Fixed 200 mg</td>
<td>Over 30 minutes every 3 weeks&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Treatment should continue until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.</td>
</tr>
<tr>
<td>First-line Advanced RCC in Combination With Axitinib</td>
<td>No</td>
<td>Fixed 200 mg, in combination with 5 mg axitinib</td>
<td>Over 30 minutes every 3 weeks&lt;sup&gt;b&lt;/sup&gt;; axitinib is administered orally twice daily</td>
<td></td>
</tr>
<tr>
<td>Adult Patients With Advanced MSI-H Cancer</td>
<td>MSI or MMR</td>
<td>Fixed 200 mg</td>
<td>Over 30 minutes every 3 weeks&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Treatment should continue until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.</td>
</tr>
<tr>
<td>Children With Advanced MSI-H Cancer</td>
<td>MSI or MMR</td>
<td>Weight-based 2 mg/kg (up to a maximum of 200 mg)</td>
<td>Over 30 minutes every 3 weeks&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Treatment should continue until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.</td>
</tr>
</tbody>
</table>

<sup>a</sup>Tumor proportion score (TPS) as determined by an FDA-approved test.

<sup>b</sup>When administering KEYTRUDA in combination with chemotherapy, administer KEYTRUDA prior to chemotherapy when given on the same day. Refer to the Prescribing Information for the chemotherapy agents administered in combination with KEYTRUDA for recommended dosing information, as appropriate.

### SELECTED SAFETY INFORMATION (continued)

#### Immune-Mediated Endocrinopathies

- KEYTRUDA can cause hypophysitis, thyroid disorders, and type 1 diabetes mellitus. Hypophysitis occurred in 0.6% (17/2799) of patients, including Grade 2 (0.2%), 3 (0.3%), and 4 (<0.1%). Hypothyroidism occurred in 8.5% (237/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The incidence of new or worsening hypothyroidism was higher in 1185 patients with HNSCC (16%) receiving KEYTRUDA, as a single agent or in combination with platinum and FU, including Grade 3 (0.3%) hypothyroidism. Hyperthyroidism occurred in 3.4% (96/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%), and thyroiditis occurred in 0.6% (16/2799) of patients, including Grade 2 (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 0.2% (6/2799) of patients.
### DOSING AND TESTING REQUIREMENTS FOR KEYTRUDA (continued)

<table>
<thead>
<tr>
<th>Indication</th>
<th>Testing Required</th>
<th>Dose</th>
<th>Administered Intravenously</th>
<th>Duration of Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adult Patients With Refractory or Relapsed cHL</strong></td>
<td>No</td>
<td>Fixed 200 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pediatric Patients With Refractory or Relapsed cHL</strong></td>
<td>No</td>
<td>Weight-based 2 mg/kg (up to a maximum of 200 mg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adult Patients With Refractory or Relapsed PMBCL</strong></td>
<td>No</td>
<td>Fixed 200 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pediatric Patients With Refractory or Relapsed PMBCL</strong></td>
<td>No</td>
<td>Weight-based 2 mg/kg (up to a maximum of 200 mg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>First-line Locally Advanced or mUC, Patients Ineligible for Cisplatin Chemotherapy</strong></td>
<td>PD-L1 expression (CPS ≥10)</td>
<td></td>
<td>Over 30 minutes every 3 weeks</td>
<td>Treatment should continue until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.</td>
</tr>
<tr>
<td><strong>First-line Locally Advanced or mUC, Patients Ineligible for Any Platinum Chemotherapy</strong></td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Second-line Locally Advanced or mUC</strong></td>
<td>No</td>
<td>Fixed 200 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>First-line Metastatic or Unresectable, Recurrent HNSCC in Combination With Platinum and FU</strong></td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>First-line Metastatic or Unresectable, Recurrent HNSCC</strong></td>
<td>PD-L1 expression (CPS ≥1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Second-line Metastatic or Recurrent HNSCC</strong></td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5

**SELECTED SAFETY INFORMATION (continued)**

**Immune-Mediated Endocrinopathies (continued)**

- Monitor patients for signs and symptoms of hypophysitis (including hypopituitarism and adrenal insufficiency), thyroid function (prior to and periodically during treatment), and hyperglycemia. For hypophysitis, administer corticosteroids and hormone replacement as clinically indicated. Withhold KEYTRUDA for Grade 2 and withhold or discontinue for Grade 3 or 4 hypophysitis. Administer hormone replacement for hypothyroidism and manage hyperthyroidism with thionamides and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes, and withhold KEYTRUDA and administer antihyperglycemics in patients with severe hyperglycemia.

**Immune-Mediated Nephritis and Renal Dysfunction**

- KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 0.3% (9/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3 (0.1%), and 4 (<0.1%) nephritis. Nephritis occurred in 1.7% (7/405) of patients receiving KEYTRUDA in combination with pemetrexed and platinum chemotherapy. Monitor patients for changes in renal function. Administer corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for Grade 2; permanently discontinue for Grade 3 or 4 nephritis.

Before prescribing KEYTRUDA, please read the accompanying Prescribing Information. The Medication Guide also is available.
SELECTED SAFETY INFORMATION (continued)

Immune-Mediated Skin Reactions
- Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative dermatitis, and bullous pemphigoid, can occur. Monitor patients for suspected severe skin reactions and based on the severity of the adverse reaction, withhold or permanently discontinue KEYTRUDA and administer corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA and refer the patient for specialized care for assessment and treatment. If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.

Other Immune-Mediated Adverse Reactions
- Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue in patients receiving KEYTRUDA and may also occur after discontinuation of treatment. For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm etiology or exclude other causes. Based on the severity of the adverse reaction, withhold KEYTRUDA and administer corticosteroids. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Based on limited data from clinical studies in patients whose immune-related adverse reactions could not be controlled with corticosteroid use, administration of other systemic immunosuppressants can be considered. Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less following corticosteroid taper. Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs and for any life-threatening immune-mediated adverse reaction.
- The following clinically significant immune-mediated adverse reactions occurred in less than 1% (unless otherwise indicated) of 2799 patients: arthritis (1.5%), uveitis, myositis, Guillain-Barré syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and encephalitis. In addition, myelitis and myocarditis were reported in other clinical trials, including classical Hodgkin lymphoma, and postmarketing use.
- Treatment with KEYTRUDA may increase the risk of rejection in solid organ transplant recipients. Consider the benefit of treatment vs the risk of possible organ rejection in these patients.
SELECTED SAFETY INFORMATION (continued)

Infusion-Related Reactions
• KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in 0.2% (6/2799) of patients. Monitor patients for signs and symptoms of infusion-related reactions. For Grade 3 or 4 reactions, stop infusion and permanently discontinue KEYTRUDA.

Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
• Immune-mediated complications, including fatal events, occurred in patients who underwent allogeneic HSCT after treatment with KEYTRUDA. Of 23 patients with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6 (26%) developed graft-versus-host disease (GVHD) (1 fatal case) and 2 (9%) developed severe hepatic veno-occlusive disease (VOD) after reduced-intensity conditioning (1 fatal case). Cases of fatal hyperacute GVHD after allogeneic HSCT have also been reported in patients with lymphoma who received a programmed death receptor-1 (PD-1) receptor—blocking antibody before transplantation. Follow patients closely for early evidence of transplant-related complications such as hyperacute GVHD, Grade 3 to 4 acute GVHD, steroid-requiring febrile syndrome, hepatic VOD, and other immune-mediated adverse reactions.
• In patients with a history of allogeneic HSCT, acute GVHD (including fatal GVHD) has been reported after treatment with KEYTRUDA. Patients who experienced GVHD after their transplant procedure may be at increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA vs the risk of GVHD in these patients.

Increased Mortality in Patients With Multiple Myeloma
• In trials in patients with multiple myeloma, the addition of KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of these patients with a PD-1 or PD-L1 blocking antibody in this combination is not recommended outside of controlled trials.

Embryofetal Toxicity
• Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. Advise women of this potential risk. In females of reproductive potential, verify pregnancy status prior to initiating KEYTRUDA and advise them to use effective contraception during treatment and for 4 months after the last dose.

Adverse Reactions
• The most common adverse reactions (≥20%) were fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhea, nausea, rash, pyrexia, cough, dyspnea, constipation, pain, and abdominal pain.
• When KEYTRUDA was used in combination with chemotherapy, the most common adverse reactions (≥20%) were fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, and stomatitis.
• When KEYTRUDA was used in combination with axitinib, the most common adverse reactions (≥20%) were diarrhea, fatigue/asthenia, hypertension, hepatotoxicity, hypothyroidism, decreased appetite, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, and constipation.

Lactation
• Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the final dose.

Pediatric Use
• There is limited experience in pediatric patients. In a trial, 40 pediatric patients (16 children aged 2 years to younger than 12 years and 24 adolescents aged 12 years to 18 years) with various cancers, including unapproved usages, were administered KEYTRUDA 2 mg/kg every 3 weeks. Patients received KEYTRUDA for a median of 3 doses (range 1–17 doses), with 34 patients (85%) receiving 2 doses or more. The safety profile in these pediatric patients was similar to that seen in adults; adverse reactions that occurred at a higher rate (≥15% difference) in these patients when compared to adults under 65 years of age were fatigue (45%), vomiting (38%), abdominal pain (28%), increased transaminases (28%), and hyponatremia (18%).

Before prescribing KEYTRUDA, please read the accompanying Prescribing Information. The Medication Guide also is available.